These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 36033902)
1. IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction]. Onco Targets Ther; 2022; 15():871-872. PubMed ID: 36033902 [TBL] [Abstract][Full Text] [Related]
2. Erratum: IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]. Onco Targets Ther; 2020; 13():12253-12254. PubMed ID: 33273830 [TBL] [Abstract][Full Text] [Related]
3. IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells. Li Y; Chen G; Han Z; Cheng H; Qiao L; Li Y Onco Targets Ther; 2020; 13():9721-9730. PubMed ID: 33061451 [TBL] [Abstract][Full Text] [Related]
4. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617 [TBL] [Abstract][Full Text] [Related]
5. LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells. Liu Y; Chen L; Yuan H; Guo S; Wu G Onco Targets Ther; 2020; 13():1145-1157. PubMed ID: 32103983 [TBL] [Abstract][Full Text] [Related]
6. miR-125a Restrains Cell Migration and Invasion by Targeting STAT3 in Gastric Cancer Cells [Retraction]. Onco Targets Ther; 2020; 13():6847. PubMed ID: 32764972 [TBL] [Abstract][Full Text] [Related]
13. Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway [Retraction]. Cancer Manag Res; 2021; 13():9027-9028. PubMed ID: 34916846 [TBL] [Abstract][Full Text] [Related]
14. Correlations of Microvascular Blood Flow of Contrast-Enhanced Ultrasound and HGF/c-Met Signaling Pathway with Clinicopathological Features and Prognosis of Patients with Hepatocellular Carcinoma [Retraction]. Onco Targets Ther; 2022; 15():1043-1044. PubMed ID: 36176729 [TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of SLP-2 in Hepatocellular Carcinoma Tissues and Its Regulation in Cancer Cell Proliferation, Migration, and EMT [Retraction]. Onco Targets Ther; 2022; 15():869-870. PubMed ID: 36003327 [TBL] [Abstract][Full Text] [Related]
16. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. Hung MH; Tai WT; Shiau CW; Chen KF World J Gastroenterol; 2014 Nov; 20(41):15269-74. PubMed ID: 25386075 [TBL] [Abstract][Full Text] [Related]
17. Effects of Combined Inhibition of STAT3 and VEGFR2 Pathways on the Radiosensitivity of Non-Small-Cell Lung Cancer Cells [Retraction]. Onco Targets Ther; 2022; 15():1045-1046. PubMed ID: 36176730 [TBL] [Abstract][Full Text] [Related]
18. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655 [TBL] [Abstract][Full Text] [Related]
19. LINC02476 Promotes the Malignant Phenotype of Hepatocellular Carcinoma by Sponging miR-497 and Increasing HMGA2 Expression [Retraction]. Onco Targets Ther; 2022; 15():145-146. PubMed ID: 35173447 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA 628 Suppresses Migration and Invasion of Breast Cancer Stem Cells through Targeting SOS1 [Retraction]. Onco Targets Ther; 2023; 16():421-422. PubMed ID: 37359350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]